[go: up one dir, main page]

TN2017000538A1 - Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions - Google Patents

Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Info

Publication number
TN2017000538A1
TN2017000538A1 TNP/2017/000538A TN2017000538A TN2017000538A1 TN 2017000538 A1 TN2017000538 A1 TN 2017000538A1 TN 2017000538 A TN2017000538 A TN 2017000538A TN 2017000538 A1 TN2017000538 A1 TN 2017000538A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
inflammatory conditions
treating ocular
ocular inflammatory
integrin alpha4
Prior art date
Application number
TNP/2017/000538A
Other languages
English (en)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of TN2017000538A1 publication Critical patent/TN2017000538A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TNP/2017/000538A 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions TN2017000538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
TN2017000538A1 true TN2017000538A1 (en) 2019-04-12

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2017/000538A TN2017000538A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Country Status (21)

Country Link
US (3) US10413535B2 (ru)
EP (1) EP3319639B1 (ru)
JP (2) JP6752276B2 (ru)
KR (2) KR102440162B1 (ru)
CN (1) CN107921136A (ru)
AU (1) AU2016290197B2 (ru)
BR (1) BR112018000112A2 (ru)
CA (1) CA2989522C (ru)
CL (1) CL2018000057A1 (ru)
ES (1) ES2835274T3 (ru)
HK (1) HK1247120A1 (ru)
IL (2) IL256770B (ru)
MA (2) MA42016A1 (ru)
MX (1) MX385229B (ru)
MY (1) MY187552A (ru)
PL (1) PL3319639T3 (ru)
RU (1) RU2018103940A (ru)
TN (1) TN2017000538A1 (ru)
UA (1) UA123728C2 (ru)
WO (1) WO2017006272A1 (ru)
ZA (1) ZA201708601B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524045B2 (en) 2017-03-09 2022-12-13 Allysta Pharmaceuticals, Inc. Peptides for dry eye disease
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN114173802A (zh) * 2019-07-26 2022-03-11 急速制药有限责任公司 用于治疗非渗出性黄斑变性和其他眼睛病症的肽
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
EP2444079B1 (en) * 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
RU2018103940A (ru) 2019-08-08
MX385229B (es) 2025-03-14
EP3319639A1 (en) 2018-05-16
IL256770A (en) 2018-03-29
RU2018103940A3 (ru) 2019-09-03
MA44935A1 (fr) 2019-08-30
CA2989522C (en) 2022-10-18
UA123728C2 (uk) 2021-05-26
JP6752276B2 (ja) 2020-09-09
MA42016A1 (fr) 2018-03-30
US20200405703A1 (en) 2020-12-31
ES2835274T3 (es) 2021-06-22
CA2989522A1 (en) 2017-01-12
ZA201708601B (en) 2019-05-29
PL3319639T3 (pl) 2021-03-08
US10751334B2 (en) 2020-08-25
AU2016290197A1 (en) 2018-01-04
BR112018000112A2 (pt) 2018-09-04
US20180200240A1 (en) 2018-07-19
CN107921136A (zh) 2018-04-17
KR102440162B1 (ko) 2022-09-02
KR20180041122A (ko) 2018-04-23
EP3319639B1 (en) 2020-11-18
CL2018000057A1 (es) 2018-06-22
WO2017006272A1 (en) 2017-01-12
JP2020121985A (ja) 2020-08-13
AU2016290197B2 (en) 2021-07-22
KR20220062688A (ko) 2022-05-17
IL280827A (en) 2021-04-29
JP2018521126A (ja) 2018-08-02
IL256770B (en) 2021-02-28
MY187552A (en) 2021-09-29
US20200000786A1 (en) 2020-01-02
HK1247120A1 (zh) 2018-09-21
US10413535B2 (en) 2019-09-17
MX2017017163A (es) 2018-08-09

Similar Documents

Publication Publication Date Title
TN2017000538A1 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
SA518391624B1 (ar) Ror- منظمات جاما
PH12018501920B1 (en) Bromodomain inhibitors
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2015012005A (es) Inhibidores de bromodominio.
MX379156B (es) Agonistas de triazol del receptor apj.
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
EA201991123A1 (ru) ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
MY200962A (en) Amide Derivatives As Nav1.7 And Nav1.8 Blockers
NZ746468A (en) Methods of treating ocular conditions
EA201791009A1 (ru) Композиции, содержащие циклоспорин
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
MX2019004375A (es) Inhibidores de bromodominios.
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний